Clinical Trial

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-27; most recent amendment 2026-05-07.
Status change: Recruiting → Active, Not Recruiting 2026-05-07
Status change: Not Yet Recruiting → Recruiting 2025-09-24
Trial Details
NCT Number NCT07042594
Lead Sponsor Suzhou Ribo Life Science Co. Ltd.
Conditions Healthy Volunteers
Enrollment 32 participants
Start Date 2025-08-26
Primary Completion 2026-06 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-08